ArticlePCN reports : psychiatry and clinical neurosciences2026
CAT-Hokkaido: A tablet-based assessment of cognitive impairment in schizophrenia.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: From causal circuit mapping to clinical translation: Prefronto-thalamic hypoconnectivity in schizophrenia.PCN reports : psychiatry and clinical neurosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Cognitive impairment is a core feature of schizophrenia and is typically assessed using paper-and-pencil neuropsychological batteries. However, these traditional methods are time-consuming and place a substantial burden on examiners before, during, and after administration. To address this issue, we developed CAT-Hokkaido, a brief tablet-based cognitive assessment tool designed to assess multiple neurocognitive domains while reducing examiner burden. Methods: We assessed its validity in a sample of 50 individuals with schizophrenia and 50 healthy controls, using the MATRICS Consensus Cognitive Battery (MCCB) as a reference standard. Group differences in CAT-Hokkaido and MCCB scores were analyzed. Results: CAT-Hokkaido identified significant performance deficits in four out of six tasks among patients with schizophrenia. These four tests evaluated processing speed, executive function, sustained attention, and verbal learning. Additionally, all tasks demonstrated significant correlations with their corresponding MCCB measures, supporting the tool's convergent validity. Conclusion: These findings suggest that CAT-Hokkaido may serve as a surrogate tool for assessing cognitive impairment in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.